Clearmind files 3 U.S. patent applications on LSD, ketamine, ibogaine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Clearmind files 3 U.S. patent applications on LSD, ketamine, ibogaine

Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations

September 23, 2026 7:57 AM EDT

The covered applications address potential therapeutic uses across a range of indications, including mental health disorders, such as depression and PTSD as well as substance use disorders

Vancouver, Canada, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the Company), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (AUD), today announced the publication in the United States of three patent applications covering novel proprietary combinations of lysergic acid diethylamide (LSD), ketamine and ibogaine with N-acylethanolamines, such as palmitoylethanolamide (PEA). The covered... More